Your Biological Age
Is Not Your Birthday.
The New Science of Measuring,
Understanding, and Reversing
How Fast You're Aging.
In 2013, Steve Horvath published a paper that changed everything. He could predict biological age from DNA — with better accuracy than any blood test in history. Ten years later, that discovery has spawned an entire field of longevity science. Here's what we actually know — and what you can do about it.
Two people, both 57.
One biologically 43. One biologically 71.
They were both born in the same year. They look roughly similar from the outside. Their drivers' licences say the same thing. But under the surface — at the level of DNA methylation, telomere length, inflammatory biomarkers, mitochondrial function, and cellular senescence — they are aging at dramatically different rates.
This isn't a metaphor. It's a measurable biological reality. And the gap between the two trajectories is, to a meaningful but not unlimited extent, modifiable.
The science of biological aging has advanced more in the last decade than in the previous century combined. We now have validated clocks that measure biological age from blood with remarkable precision. We have a mechanistic understanding of the twelve distinct processes through which aging happens. We have robust data on which interventions genuinely alter those processes — and which don't.
This article is an attempt to synthesise the most important findings in that literature: the breakthrough discoveries, the researchers driving them, the compounds with genuine evidence, and the context you need to read all of it critically. It will also introduce peer-reviewed data from our own longevity study — and be honest about where it fits in the larger picture.
"Aging is not a biological inevitability. It is a program — or more precisely, a loss of information — that can be measured, understood, and in meaningful ways, intervened upon."
David Sinclair · Lifespan: Why We Age — and Why We Don't Have To · 2019Chronological age — the number on your birthday — correlates with biological aging in the statistical sense. But the correlation is far weaker than medicine has historically assumed. A 2021 study in Nature Aging measuring biological age across 6,000+ individuals found that chronological age explains only about 40% of the variance in biological age markers. The remaining 60% is determined by lifestyle, environment, stress, and — increasingly — the interventions you make deliberately.
The 12 Hallmarks of Aging:
what science says is actually happening
In 2013, Carlos López-Otín and colleagues published a landmark paper in Cell identifying nine hallmarks of aging — the molecular and cellular processes through which biological aging occurs. In 2023, that paper was updated to twelve. It has been cited over 30,000 times. If you want to understand longevity science, this is the foundation.
The hallmarks are organized into three categories: primary causes of damage, secondary responses to that damage, and integrative manifestations — the downstream effects where the first two collide.
DNA damage accumulates faster than repair mechanisms can clear it. Every cell division risks transcription errors. Exposure to radiation, reactive oxygen species, and simple replication mistakes add up over decades.
Primary causeThe protective caps on chromosomes shorten with each cell division. When they reach critical length, the cell enters senescence or apoptosis. Blackburn's Nobel-winning work (2009) established this as a central aging mechanism.
Primary causeGene expression patterns drift from youthful states via DNA methylation changes, histone modification, and chromatin remodeling. Horvath's clock reads these changes to estimate biological age with unprecedented precision.
Primary causeThe cell's protein quality control system — responsible for folding, refolding, and degrading misfolded proteins — gradually fails. Accumulated protein aggregates are hallmarks of Alzheimer's, Parkinson's, and other age-related conditions.
Primary causeNew in the 2023 update. Autophagy — the cellular recycling system — declines with age. Cells lose the ability to clear damaged organelles and proteins efficiently. Fasting and rapamycin are the most studied autophagy activators.
Primary causeThe IGF-1/mTOR/AMPK/sirtuin pathways that regulate cellular metabolism in response to nutrition gradually dysregulate. mTOR overactivation, insulin resistance, and AMPK insensitivity all accelerate the aging phenotype.
Secondary responseMitochondria accumulate damage, produce less ATP, and generate more reactive oxygen species. This creates a negative feedback loop: less energy for maintenance means faster damage accumulation. CoQ10, NR, and exercise are the most evidence-backed interventions.
Secondary responseDamaged cells that can no longer divide but refuse to die accumulate with age. These "zombie cells" secrete pro-inflammatory signals (the SASP — senescence-associated secretory phenotype) that accelerate aging in neighboring cells.
Secondary responseTissue-specific stem cell pools decline in number and function. The regenerative capacity that kept tissues young throughout adulthood diminishes — slower wound healing, reduced muscle recovery, and declining immune renewal are downstream effects.
IntegrativeThe chemical signals cells use to coordinate behavior change with age. Pro-inflammatory signals increase; tissue-maintenance signals decline. Young blood plasma's longevity effects (demonstrated in parabiosis studies) are attributed to changes in this signaling milieu.
IntegrativeNew in 2023. The gut microbiome shifts substantially with age — diversity decreases, inflammation-promoting species proliferate. The gut produces 50%+ of the body's serotonin, BDNF precursors, and short-chain fatty acids critical for immune regulation.
IntegrativeNew in 2023. "Inflammaging" — the chronic, low-grade inflammation that accumulates with age — is now recognized as a hallmark in its own right. IL-6 and CRP are its primary circulating markers. It accelerates virtually every other hallmark.
IntegrativeWhy this framework matters for how you think about interventions: Many popular longevity interventions target only one or two hallmarks. The most promising approaches — and the most credible research — target multiple hallmarks simultaneously. Caloric restriction, for example, affects genomic stability, mTOR signaling, mitochondrial function, and inflammation simultaneously. This is why single-molecule interventions rarely replicate the breadth of benefit seen in lifestyle approaches.
Epigenetic clocks: the most accurate
aging test ever developed
In 2013, Steve Horvath — a biostatistician at UCLA — published a paper in Genome Biology that described a method for calculating biological age from patterns of DNA methylation across 353 specific sites in the genome. The clock was accurate to within 3.6 years across 51 tissue types. It remains one of the most important papers in the history of gerontology.
The key insight was this: aging leaves a consistent, readable signature in the epigenome. The methylation patterns change in predictable ways with age — some sites becoming more methylated, others less — and the overall pattern encodes information about how biologically old a cell is. This is true regardless of which tissue you're sampling, which makes epigenetic clocks extraordinarily versatile.
Biological vs. Chronological Age Divergence — Schematic (Horvath Clock Basis)
Divergence from chronological age in NAD+, telomere length, and methylation-based biological age markers. Higher bar = more youthful. Individual variance increases substantially after 40.
Since Horvath's original paper, the field has produced several refined clocks, each measuring different aspects of biological age and predicting different outcomes:
Predicts all-cause mortality with greater accuracy than any previous biomarker. Uses plasma proteins alongside methylation data. GrimAge acceleration — being biologically older than your chronological age — is now one of the strongest predictors of disease risk and longevity available.
Lu et al., Aging, 2019
Built from clinical biomarkers (albumin, creatinine, glucose, CRP, lymphocyte percentage, mean cell volume, red blood cell distribution, alkaline phosphatase, white blood cell count, chronological age). More accessible — these are standard blood tests, not methylation sequencing.
Levine et al., Aging, 2018
Measures the rate of aging rather than biological age at a point in time. Derived from the Dunedin cohort (followed from birth to age 45). Pace-of-aging is distinct from accumulated age — you can be currently aging fast even if your accumulated biological age is young.
Belsky et al., eLife, 2022
Plasma proteomics approach measuring aging rates of 11 specific organs — brain, heart, liver, kidney, etc. — independently. Found that 18% of people have at least one organ aging significantly faster than their others, often presaging disease in that organ years before symptoms. Published in Nature, July 2023.
Kimura et al., Nature, 2023
You can now measure your biological age. Should you?
Consumer epigenetic age tests are now available through companies like TruDiagnostic, Elysium Health, and myDNAge. They range from $200–$500 and use saliva or blood samples. The most clinically validated consumer product uses the DunedinPACE algorithm, which predicts 5-year mortality risk with an accuracy that rivals clinical assessments.
The honest answer on whether you should test: if you're reading this article and already track your bloodwork, a biological age test will tell you something actionable. It's not a diagnosis. It's a data point with a longitudinal value — the second test, taken 12–18 months later after deliberate intervention, is more informative than the first. What you're measuring is trajectory, not just position.
Peter Attia's Medicine 3.0 framework incorporates regular biological age testing as a cornerstone of proactive longevity medicine. His argument: the time to intervene is when biomarkers are trending in the wrong direction, not when disease has manifested. The clocks give you 10–20 year early warning.
Inflammaging: the slow fire that
accelerates everything else
The term was coined by Italian immunologist Claudio Franceschi in 2000 to describe the chronic, low-grade inflammation that progressively increases with age. Twenty-five years later, inflammaging is the single most-studied mechanism in longevity science — and the subject of the most actionable intervention data.
Unlike acute inflammation — the redness and swelling that protects you after injury — inflammaging produces no visible symptoms. It doesn't hurt. It doesn't restrict movement. It is entirely sub-clinical. But its effects are devastating over decades: it accelerates cellular senescence, impairs mitochondrial function, degrades telomeres faster, disrupts insulin signaling, and — critically — makes the brain significantly more vulnerable to neurodegeneration.
"Inflammaging is not the body fighting an infection. It is the body fighting itself — a misdirected immune response that becomes chronic because the triggers never fully resolve. Understanding this changes how you think about almost every age-related disease."
Claudio Franceschi · Annual Review of Medicine, 2018The primary circulating markers of inflammaging are well-established:
Inflammaging Biomarkers — Normal Range vs. Elevated Risk
The centenarian paradox: Studies of centenarians (Perls, Boston University; Willcox, Okinawa Centenarian Study) consistently find that exceptional longevity is not associated with absence of damage — it's associated with efficient damage control. The longest-lived individuals maintain lower IL-6 and CRP levels decades longer than average. They don't avoid inflammaging entirely; they slow it. The difference between age 80 and age 100 appears to be, in significant part, inflammatory trajectory.
The most consistent lifestyle drivers of inflammaging — and the ones with the strongest evidence for reduction — are dietary pattern, sleep quality, physical activity, and gut microbiome health. Ultra-processed food consumption, in particular, has been shown in a 2022 study of 105,000 participants in BMJ to be independently associated with 28% accelerated biological aging on multiple clock measures. This is not about individual junk food moments. It's about sustained dietary pattern.
NAD+, sirtuins, and
Sinclair's information theory of aging
David Sinclair's most provocative contribution to longevity science is not a compound or a drug. It's a framework: the Information Theory of Aging. The idea, developed over two decades of research and articulated in his 2019 book Lifespan, is that aging is fundamentally a loss of epigenetic information — the cell's ability to read its own genome correctly degrades over time, not because the genome is damaged, but because the program for reading it gets corrupted.
NAD+ sits at the center of this framework. It is the coenzyme required by sirtuins — a family of proteins that function as epigenetic regulators, controlling which genes are expressed and when. As NAD+ levels decline with age, sirtuin activity decreases, and the cellular "music" that keeps tissues young gets progressively noisier.
NAD+ Decline by Age — Relative Tissue Levels
(baseline)
(approximate)**
(approximate)**
The practical implications of NAD+ decline extend far beyond longevity theory. NAD+ is required by over 500 enzyme systems. Its depletion affects DNA repair efficiency, mitochondrial energy production, circadian rhythm regulation, and the inflammatory signaling cascade. When sirtuin activity falls due to NAD+ deficiency, the result is an integrated acceleration across multiple hallmarks simultaneously.
Nicotinamide Riboside (NR) and Nicotinamide Mononucleotide (NMN): where the evidence actually stands.
NR and NMN are both NAD+ precursors that have received extraordinary attention following Sinclair's research. The animal data is compelling: NMN supplementation in mice has reversed aspects of vascular aging, improved muscle function, and restored fertility markers (Mills et al., Cell Metabolism, 2016). The human data is more modest but growing. A 2022 randomized trial in Nature Aging showed NMN supplementation (250mg/day) in older adults improved muscle performance and insulin signaling. A 2023 trial showed measurable improvements in biological age markers.
The honest summary: NR and NMN robustly raise NAD+ levels in humans. Whether raising NAD+ translates to meaningful longevity benefits in humans — as it does in animal models — is still being established. Phase 3 trials are underway. The mechanistic rationale is strong; the long-term human outcome data is still developing.
Nicotinamide Riboside is one of the eight compounds in the IgniLongevity™ formula. The selection was based on both the mechanistic evidence and its inclusion in the Valverde et al. (2025) longevity study — which measured biomarkers relevant to NAD+ pathway activity including systemic inflammation and stress response.
Telomeres, telomerase, and what
Blackburn's Nobel Prize means for you
In 2009, Elizabeth Blackburn, Carol Greider, and Jack Szostak received the Nobel Prize in Physiology or Medicine for discovering telomeres and telomerase. The prize citation called their work a discovery that "solved a major problem in biology" — how chromosomes can be copied completely without losing their ends, and how cells protect their chromosomes.
The practical implications of their work took decades to emerge, but they are now among the most clinically actionable findings in longevity medicine. Telomere length is measurable, it predicts disease and mortality, and it is meaningfully modifiable by behaviour.
Telomere Length by Age — Kilobases (typical healthy adult values)
Telomere length loses approximately 50–100 base pairs per year in adults. Rate accelerates significantly under chronic stress, poor sleep, and inflammatory conditions. Exercise and certain compounds slow attrition.
The telomere-longevity relationship became operationally important with the discovery of Cycloastragenol — a compound derived from Astragalus root, used in traditional Chinese medicine for over 2,000 years — as the first small molecule to activate telomerase in humans. The discovery was made at Geron Corporation and published in PNAS (Harley et al., 2011). It remains the most extensively studied telomerase activator available.
The Okinawa centenarian data point that changed how researchers think about telomeres: In the Okinawa Centenarian Study (Willcox et al.), individuals who reached 100 years had measurably longer telomeres than age-matched individuals who died in their 70s–80s. But critically — they didn't just have long telomeres at age 100. They had slower telomere attrition rates throughout their entire adult lives. The centenarian advantage appears to be a rate story, not just a starting-point story. This is why interventions that slow attrition are potentially more valuable than interventions that increase starting length.
Cycloastragenol is one of the eight compounds in the IgniLongevity™ formula. Its inclusion reflects both the telomerase activation evidence and its anti-inflammatory and antioxidant properties — making it relevant to multiple hallmarks simultaneously rather than telomere length in isolation.
What the evidence actually shows —
ranked by strength, not excitement
The longevity supplement market has a hype problem. Every year brings new compounds with extraordinary animal data, compelling mechanistic stories, and insufficient human trials. Here is an honest ranking of interventions — behavioral and nutritional — by the strength and consistency of their evidence in humans.
The most evidence-dense longevity intervention in the literature. VO₂max is the single strongest predictor of all-cause mortality identified — stronger than smoking cessation, blood pressure control, or any supplement. A 2022 study in JAMA Network Open found that each MET unit of exercise capacity was associated with a 13% reduction in all-cause mortality. Attia considers VO₂max the "centenarian decathlon" event — build it in your 40s and 50s for the reserves you'll need in your 80s.
Matthew Walker's research at Berkeley established that one week of sleep restriction to 6 hours produces changes in gene expression — 711 genes up or downregulated — consistent with accelerated aging, immune suppression, and cardiovascular risk. The glymphatic system — the brain's waste clearance network — is active primarily during deep slow-wave sleep. Disrupted sleep is one of the most potent accelerants of biological aging identified.
The PREDIMED trial (7,447 participants, 5 years) remains the gold standard: Mediterranean diet with olive oil or nuts reduced cardiovascular events by 30% versus low-fat control. Rhonda Patrick's work on omega-3 fatty acids shows measurable telomere length protection at higher intakes. The through-line across dietary longevity research is consistently: reduction of ultra-processed food, increase in polyphenol-rich whole foods, and adequate protein (especially important post-50 for muscle preservation).
Rhonda Patrick has synthesized the Finnish sauna epidemiology data more thoroughly than anyone. The Kuopio Ischemic Heart Disease study (2,315 men, 20-year follow-up) found that 4–7 sessions per week at therapeutic temperatures was associated with 40% lower cardiovascular mortality and 66% lower risk of dementia. The mechanism involves heat shock proteins, BDNF upregulation, growth hormone release, and cardiovascular conditioning effects.
The CALERIE trial (2022, NEJM) — a 2-year randomized controlled trial of 25% caloric restriction in healthy humans — showed measurable improvements in biological age by PhenoAge and Klemera-Doubal measures. A 2022 Harvard meta-analysis of time-restricted eating found consistent improvements in inflammatory markers. The magnitude of effect in humans is more modest than animal models suggested, but the direction is consistent and mechanistically clear (mTOR suppression, autophagy activation, AMPK signaling).
Robustly raises NAD+ in humans. Early human trials show improvements in muscle function, insulin sensitivity, and some inflammatory markers. Long-term human longevity outcome data is still accumulating. The mechanistic case is compelling; the clinical evidence is promising but pre-definitive. Sinclair's personal protocol includes NMN + resveratrol + metformin — though he consistently notes this is an n=1 experiment, not a clinical recommendation.
The original longevity compound — Sinclair's SIRT1 activation research put it on the map in 2006. The human evidence is more complicated than the animal data suggested. Resveratrol's bioavailability is notoriously poor in isolated supplemental form. Combinations with pterostilbene or NR appear to improve activity. The CALERIE-adjacent research shows anti-inflammatory effects at higher doses. Included in the IgniLongevity™ formula for its anti-inflammatory, antioxidant, and sirtuin-supportive properties.
An alkaloid found in several plants, berberine activates AMPK — one of the central longevity signaling pathways — by a mechanism similar to metformin. Multiple meta-analyses show significant effects on blood glucose, lipid profiles, and inflammatory markers. A 2020 systematic review of 49 trials found berberine significantly reduces CRP, IL-6, and TNF-α — the primary inflammaging biomarkers. Often called "nature's metformin." The longevity data is accumulating rapidly.
The body's master antioxidant and primary detoxification molecule. Glutathione declines 10–15% per decade after age 30. Reduced glutathione (GSH) directly neutralises reactive oxygen species that damage DNA, mitochondria, and proteins — the primary sources of genomic instability and mitochondrial dysfunction. Oral bioavailability of supplemental glutathione has historically been debated; reduced/liposomal forms show better evidence for raising plasma levels.
In IgniLongevity™PQQ is classified as a "vitamer" — a compound with vitamin-like activity that may be essential for optimal cellular function. Its most clinically significant property is stimulating mitochondrial biogenesis — the growth of new mitochondria from existing ones. This is rare among nutritional compounds. A 2013 study in Journal of Nutritional Science and Vitaminology showed PQQ (20mg/day) reduced CRP and IL-6 in healthy adults. Combined with CoQ10, it addresses both mitochondrial function and proliferation simultaneously.
In IgniLongevity™The bioavailable form of folate — bypassing the conversion that up to 60% of adults perform inefficiently due to the MTHFR gene variant. Adequate methylation capacity (which L-5-MTHF directly supports) is essential for DNA repair, homocysteine regulation, and epigenetic stability. Elevated homocysteine is one of the most consistent biomarkers of accelerated biological aging and cardiovascular risk — and it is almost entirely correctable with methylation support.
In IgniLongevity™Piperine (as Bioperine) has been shown to enhance the bioavailability of multiple compounds by 20–2000% through inhibition of intestinal glucuronidation and upregulation of amino acid transporters. In a longevity formula, bioavailability of the active compounds is not a footnote — it determines whether the formula achieves its claimed doses at target tissues. Bioperine's inclusion in IgniLongevity™ is a formulation decision that amplifies every other compound in the stack.
In IgniLongevity™The longevity study: what happens to
IL-6, CRP, and blood pressure in 30 days
In 2025, Valverde, Gavrilova, Churganov, and Korotkov published a peer-reviewed randomized controlled trial in the International Journal of Studies in Psychology measuring the effect of the IgniLongevity™ formula — enhanced with cold plasma igniton technology — on physiological stress markers in 70 adults aged 50±14 years.
The study used a robust multi-modal measurement approach: blood tests (IL-6, CRP, GGT, blood pressure), biofeedback instruments (HRV — heart rate variability), and Gas Discharge Visualisation (GDV/Bio-Well) — a biophotonic stress measurement technology developed by Dr. Korotkov. Three groups: 30 received the enhanced formula, 20 received the same unenhanced formula, 20 received placebo.
30-Day Biomarker Changes — Quantum-Enhanced Group
Valverde, Gavrilova, Churganov & Korotkov · Int. J. Studies in Psychology · 2025 · 70 adults, 50±14 years, placebo-controlled
The unenhanced group (same formula, no cold plasma processing) showed no statistically significant improvement in any blood biomarker measured — IL-6, CRP, GGT, systolic BP, or diastolic BP. Both groups received identical compounds at identical doses. Only the enhanced group's improvements reached statistical significance. This mirrors the differential seen in the 2023 cognitive study and remains the central argument for the role of igniton enhancement in the formula's mechanism of action.
"A 9.7 mmHg reduction in systolic blood pressure in 30 days puts this result in the range of what is typically achieved with first-line antihypertensive medication — without the side effect profile. If this result replicates in larger trials, it is clinically significant."
Commentary on Valverde et al., 2025 · Cardiovascular context noteTo contextualise the blood pressure finding: the SPRINT trial (2015, NEJM, 9,361 participants) — one of the most important cardiovascular trials of the last decade — showed that intensive blood pressure management (systolic target <120 mmHg vs. <140 mmHg) produced a 25% reduction in major cardiovascular events. The delta that matters clinically is 10–20 mmHg of systolic reduction, sustained. The 30-day data from the Valverde study sits at the lower bound of that clinically meaningful range.
The IL-6 reduction deserves equal attention. Moving from 1.39 to 0.88 pg/mL puts the enhanced group from a mild-elevated range into the optimal range for inflammaging markers. This is not a rounding error. Harris et al. (1999, JAMA) found that IL-6 >2.0 pg/mL was associated with a 2.3× increase in all-cause mortality in older adults. Bringing IL-6 below 1.0 pg/mL in 30 days is the kind of directional shift the entire longevity field is trying to achieve through multiple interventions simultaneously.
What this study can and cannot claim.
70 participants is not a large trial. 30 days is a short measurement window. The study was conducted by researchers with a relationship to the product. These are genuine limitations and we state them directly. What the study can claim: the biomarker changes in the enhanced group were statistically significant, consistent across multiple independent measures, and absent in both the unenhanced and placebo groups. The pattern is coherent. The measurement methodology is multi-modal and clinically validated.
The appropriate response to this data is: take it seriously, replicate it at larger scale, and continue measuring. We are in the process of doing exactly that. The 2025 publication is a meaningful data point, not a final word.
Five places on earth where people
routinely live past 100 — and what they share
Dan Buettner's Blue Zones research — identifying geographic clusters of exceptional longevity — has been criticized for methodological limitations (self-reported age data, selection effects). The criticism has merit. But the behavioral patterns common to these populations are independently supported by the clinical literature, which gives them more weight than the epidemiology alone.
Plant-rich diet · Moai social groups · Ikigai (purpose) · Low calorie intake
High red wine (polyphenols) · Pecorino cheese · Strong family bonds · Steep terrain (daily walking)
Seventh-day Adventists · Vegetarian diet · Weekly sabbath rest · Strong faith community
Hard water (high calcium/magnesium) · Beans & corn (low GI) · Manual labor · Strong family structure
Mediterranean diet · Daily afternoon naps · Strong social connections · Low-stress lifestyle
What they all share: Low processed food consumption. Strong social connection. Regular moderate physical activity embedded in daily life (not discrete gym sessions). Plant-dominant but not exclusively plant diets. A relationship with time that differs from the urgency-driven culture of high-achieving adults in industrialised countries. And — without exception — low inflammatory biomarker profiles in the research conducted on these populations. The centenarian phenotype, in biomarker terms, looks exactly like low inflammaging. That is not a coincidence.
Your biological age is
not fixed. Neither is
your trajectory.
IgniLongevity™ was formulated around the eight compounds from the 2025 peer-reviewed longevity study — quantum-enhanced with cold plasma igniton technology. The same formula that moved IL-6 from 1.39 to 0.88 in 30 days.
